Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 11/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 12/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582533 | 0.91 | ITK (0.42) | FGFR1FGFR4FGFR2FGFR3JAK3 | |
| SCHEMBL30582501 | 0.89 | EGFR (0.47) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL26587507 | 0.89 | EGFR (0.47) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL26587541 | 0.89 | FGFR1 (0.47) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL30582502 | 0.88 | FGFR1 (0.39) | FGFR1FGFR4FGFR2FGFR3JAK3 | |
| SCHEMBL30582537 | 0.87 | BTK (0.39) | FGFR1FGFR4FGFR2FGFR3JAK3 | |
| SCHEMBL26587553 | 0.87 | BTK (0.39) | FGFR1FGFR4FGFR2FGFR3JAK3 | |
| SCHEMBL30582495 | 0.87 | FGFR1 (0.40) | FGFR1FGFR4FGFR2FGFR3BTK | |
| SCHEMBL30582607 | 0.87 | HDAC2 (0.39) | EGFRJAK2 | |
| SCHEMBL26106956 | 0.87 | HDAC2 (0.39) | EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | claimed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |